Chemoinformaics analysis of exiguaflavanone B
| Molecular Weight | 438.52 | nRot | 7 |
| Heavy Atom Molecular Weight | 408.28 | nRig | 20 |
| Exact Molecular Weight | 438.204 | nRing | 3 |
| Solubility: LogS | -3.607 | nHRing | 1 |
| Solubility: LogP | 6.069 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 62 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 32 | No. of Aromatic Carbocycles | 2 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 30 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 26 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 12 |
| nHA | 6 | APOL | 68.2358 |
| nHD | 3 | BPOL | 34.4362 |
| QED | 0.486 |
| Synth | 3.955 |
| Natural Product Likeliness | 2.309 |
| NR-PPAR-gamma | 0.958 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.236 |
| Pgp-sub | 0.003 |
| HIA | 0.037 |
| CACO-2 | -4.762 |
| MDCK | 0.0000134 |
| BBB | 0.008 |
| PPB | 0.985095 |
| VDSS | 0.493 |
| FU | 0.0141334 |
| CYP1A2-inh | 0.353 |
| CYP1A2-sub | 0.936 |
| CYP2c19-inh | 0.901 |
| CYP2c19-sub | 0.43 |
| CYP2c9-inh | 0.903 |
| CYP2c9-sub | 0.965 |
| CYP2d6-inh | 0.851 |
| CYP2d6-sub | 0.675 |
| CYP3a4-inh | 0.492 |
| CYP3a4-sub | 0.356 |
| CL | 11.197 |
| T12 | 0.137 |
| hERG | 0.031 |
| Ames | 0.026 |
| ROA | 0.74 |
| SkinSen | 0.849 |
| Carcinogencity | 0.314 |
| EI | 0.863 |
| Respiratory | 0.899 |
| NR-Aromatase | 0.767 |
| Antiviral | Yes |
| Prediction | 0.800966 |